Opportunity Information: Apply for CDC RFA JG 26 0142
Apply for CDC RFA JG 26 0142
- The Centers for Disease Control-GHC in the health sector is offering a public funding opportunity titled "Ending HIV and TB as public health threats through an accelerated and sustained comprehensive response in India" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.067, 93.494.
- This funding opportunity was created on 2026-08-17.
- Applicants must submit their applications by 2026-09-16. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 2 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Unrestricted.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity, titled "Ending HIV and TB as public health threats through an accelerated and sustained comprehensive response in India" (Funding Opportunity Number: CDC RFA JG 26 0142), is a CDC Global Health cooperative agreement designed to strengthen India-led systems for controlling and ultimately ending HIV and tuberculosis as public health threats. The program is explicitly aligned with India`s national strategies, including the National AIDS Control Program (NACP)-VI and the National TB Elimination Program (NTEP), and is meant to support the National AIDS Control Organization (NACO), the Central Tuberculosis Division (CTD), and other parts of the Ministry of Health and Family Welfare (MoHFW). The overall intent is not just to fund services, but to reinforce the underlying public health infrastructure, coordination, and service delivery models that allow epidemic control to be accelerated now and sustained over time.
In terms of funding, CDC anticipates approximately $6,000,000 in total funding for Year 1, depending on the availability of appropriated funds. An unusual detail in the notice is that the "Award Ceiling" for Year 1 is listed as $0 (none), which typically signals that CDC is not setting a per-award cap in the public posting or that final award sizing will be determined through negotiation and programmatic decisions rather than a fixed maximum. The opportunity expects to make about 2 awards. The instrument type is a cooperative agreement, which generally means CDC will have substantial involvement in the work (for example, collaborating on technical approaches, monitoring performance, and shaping implementation priorities), rather than providing a more hands-off grant.
The work is centered on practical, evidence-based approaches that move countries toward epidemic control benchmarks for HIV and TB. For HIV, that includes preventing new infections, improving early case detection, ensuring that people who test positive are linked quickly and smoothly to care, supporting treatment adherence over time, and achieving viral suppression at the population level. For TB, the focus is similarly on reducing transmission and mortality through stronger detection, treatment initiation, and treatment completion, especially where TB and HIV intersect. A key theme is integration: rather than running parallel disease programs, the notice encourages integrated service delivery for HIV and co-morbidities, which in the India context often includes TB as a major co-infection and other related health needs that affect outcomes and retention in care.
The NOFO highlights several core activity areas. One is closing persistent gaps across the testing and treatment cascade for both HIV and TB, meaning identifying where people are being missed (for example, not being tested, not returning for results, not starting treatment, or falling out of care) and fixing those breakdown points with targeted, data-driven interventions. Another is delivering more integrated services for HIV and co-morbidities, which usually implies making it easier for patients to receive coordinated care through streamlined referrals, shared clinical workflows, and more patient-centered service models. The opportunity also emphasizes strengthening cooperation, coordination, and ownership, which points to improving how national and subnational stakeholders plan together, share data, manage performance, and sustain interventions with domestic leadership rather than reliance on external implementers.
A major goal running through the announcement is transition to local ownership. In practice, that often means building the capacity of government systems and local partners to manage essential services, budgets, monitoring, workforce training, supply chains, and quality improvement without long-term dependence on outside technical teams. The notice underscores collaboration with stakeholders "at all levels," suggesting engagement from national leadership down to state, district, and community layers, including civil society and service delivery partners that influence uptake and continuity of care. The intent is to ensure improvements are institutionalized inside India`s health programs so that progress continues after the period of external support.
There is also a broader health security angle: beyond HIV and TB outcomes, the NOFO frames part of the work as improving prevention, detection, and response to infectious diseases more generally. That can include strengthening surveillance, laboratory networks, outbreak readiness, and the use of routine data for rapid decision-making, all of which improve resilience against emerging threats while also improving performance for HIV and TB programs. This framing aligns the opportunity with U.S. global health priorities by tying disease-specific work to wider system capabilities that reduce mortality, prevent spread, and protect cross-border health security.
Eligibility is broad and includes a wide range of domestic U.S.-style applicant categories listed in the notice: various levels of government, public and private universities, tribal entities, nonprofits (with or without 501(c)(3) status), for-profit organizations, and small businesses. The activity category is Health, and the CFDA numbers listed are 93.067 and 93.494. The opportunity was created on 2026-08-17 and has an original closing date of 2026-09-16.
FAQs: Ending HIV and TB as public health threats through an accelerated and sustained comprehensive response in India (CDC RFA JG 26 0142)
What is the title of this funding opportunity?
The title is "Ending HIV and TB as public health threats through an accelerated and sustained comprehensive response in India."
What is the Funding Opportunity Number (FON) for this announcement?
The Funding Opportunity Number is CDC RFA JG 26 0142.
Who is offering this funding opportunity?
This opportunity is offered by CDC Global Health.
What type of award is this?
This is a cooperative agreement, which typically means CDC will have substantial involvement in the work (such as collaborating on technical approaches, monitoring performance, and helping shape implementation priorities).
What is the main goal of this cooperative agreement?
The main goal is to strengthen India-led systems to control and ultimately end HIV and tuberculosis (TB) as public health threats by accelerating progress now and sustaining it over time through stronger public health infrastructure, coordination, and service delivery models.
Is this opportunity aligned with Indias national HIV and TB strategies?
Yes. The program is explicitly aligned with Indias national strategies, including the National AIDS Control Program (NACP)-VI and the National TB Elimination Program (NTEP).
Which Indian government bodies and programs are intended to be supported?
The NOFO indicates support for the National AIDS Control Organization (NACO), the Central Tuberculosis Division (CTD), and other parts of the Ministry of Health and Family Welfare (MoHFW).
Is the funding intended primarily to pay for direct services?
The stated intent is not simply to fund services, but to reinforce underlying public health infrastructure, coordination, and service delivery models that enable epidemic control to be accelerated and sustained.
What are the primary disease areas addressed?
The primary disease areas are HIV and tuberculosis (TB), including work at the intersection of HIV and TB co-infection.
How much funding is expected for Year 1?
CDC anticipates approximately $6,000,000 in total funding for Year 1, contingent on the availability of appropriated funds.
How many awards does CDC expect to make?
The opportunity expects to make about 2 awards.
Is there an award ceiling (maximum award amount) for Year 1?
The notice lists the "Award Ceiling" for Year 1 as $0 (none). This typically suggests CDC is not setting a per-award cap in the public posting and that final award amounts may be determined through negotiation and programmatic decisions rather than a fixed maximum.
What does CDC substantial involvement mean in practice?
Because this is a cooperative agreement, CDC may be involved in collaborative technical work, performance monitoring, and shaping implementation priorities, rather than operating in a fully hands-off role.
What are the main HIV program priorities described in the NOFO?
The NOFO highlights evidence-based approaches to prevent new HIV infections, improve early case detection, ensure rapid and smooth linkage to care, support long-term treatment adherence, and achieve viral suppression at the population level.
What are the main TB program priorities described in the NOFO?
The NOFO emphasizes reducing TB transmission and mortality by strengthening detection, treatment initiation, and treatment completion, particularly where TB and HIV intersect.
What does the NOFO mean by closing gaps in the testing and treatment cascade?
It refers to identifying where people are being missed across HIV and TB testing and treatment steps (for example, not being tested, not returning for results, not starting treatment, or falling out of care) and addressing those breakdown points using targeted, data-driven interventions.
What does integrated service delivery mean in this opportunity?
Integration is a key theme, encouraging coordinated service delivery for HIV and co-morbidities (often including TB). This generally points to streamlined referrals, shared clinical workflows, and more patient-centered models so patients can receive coordinated care more easily.
What kinds of coordination or ownership improvements are emphasized?
The NOFO emphasizes strengthening cooperation, coordination, and ownership, including improving how national and subnational stakeholders plan together, share data, manage performance, and sustain interventions with domestic leadership.
How does the opportunity describe transition to local ownership?
Transition to local ownership is described as building capacity of government systems and local partners to manage essential services, budgets, monitoring, workforce training, supply chains, and quality improvement without long-term dependence on outside technical teams.
Which levels of stakeholders are expected to be engaged?
The NOFO underscores collaboration with stakeholders at all levels, suggesting engagement from national leadership down to state, district, and community layers, including civil society and service delivery partners that influence uptake and continuity of care.
Does the NOFO include a broader health security or systems strengthening angle beyond HIV and TB?
Yes. The NOFO frames part of the work as improving prevention, detection, and response to infectious diseases more generally, which can include strengthening surveillance, laboratory networks, outbreak readiness, and the use of routine data for rapid decision-making.
How does the broader health security framing relate to the HIV and TB work?
The NOFO links disease-specific work to wider system capabilities that can reduce mortality, prevent spread, and improve resilience against emerging threats while also improving HIV and TB program performance.
What is the activity category for this opportunity?
The activity category is Health.
What CFDA numbers are associated with this funding opportunity?
The CFDA numbers listed are 93.067 and 93.494.
Who is eligible to apply based on the categories listed?
Eligibility is broad and includes various levels of government, public and private universities, tribal entities, nonprofits (with or without 501(c)(3) status), for-profit organizations, and small businesses.
When was this opportunity created?
The opportunity was created on 2026-08-17.
What is the original closing date for applications?
The original closing date is 2026-09-16.
Where is the work intended to take place?
The NOFO is focused on India, with the intent to strengthen India-led systems and support Indias national HIV and TB programs.
Browse more opportunities from the same category: Health
Next opportunity: Reflective Supervision in Home Visiting Research Awards
Previous opportunity: Improving global health security in Côte d'Ivoire to stop the spread of infectious disease
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA JG 26 0142
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA JG 26 0142) also looked into and applied for these:
| Funding Opportunity |
|---|
| Improving regional capacity to respond to HIV, TB, and other global health priorities in Central America Apply for CDC RFA JG 26 0130 Funding Number: CDC RFA JG 26 0130 Agency: Centers for Disease Control-GHC Category: Health Funding Amount: Case Dependent |
| Strengthening Ghana Health Service laboratory services, diagnostic networks, and systems for a more effective, efficient, and sustainable response to HIV, TB, and other priority health threats Apply for CDC RFA JG 26 0178 Funding Number: CDC RFA JG 26 0178 Agency: Centers for Disease Control-GHC Category: Health Funding Amount: Case Dependent |
| Advancing Global Capacity to Detect and Respond to Fungal Diseases Apply for CDC RFA CK 26 0230 Funding Number: CDC RFA CK 26 0230 Agency: Centers for Disease Control - NCEZID Category: Health Funding Amount: Case Dependent |
| Pediatric Disaster Care Centers of Excellence Program Cooperative Agreement Apply for EP U3R 26 001 Funding Number: EP U3R 26 001 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: Case Dependent |
| Healthy Cooking in Communities Apply for HP DPH 26 001 Funding Number: HP DPH 26 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $10,000,000 |
| Applied Drug Policy Research Experiences Apply for RD AL RDAAL 26 001 Funding Number: RD AL RDAAL 26 001 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $100,000 |
| Nonfatal Overdoses in Emergency Departments: Bridging Patient Characteristics, Biospecimen Toxicology, and Drug Supply Composition Apply for EDS EDS 26 001 Funding Number: EDS EDS 26 001 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $500,000 |
| Improving The Capacity of Tribal Communities to Identify Emerging Drug Threats Apply for RD ET RDA 26 001 Funding Number: RD ET RDA 26 001 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $300,000 |
| Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed) Apply for RFA AG 27 010 Funding Number: RFA AG 27 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03 Clinical Trial Optional) Apply for PAR 27 096 Funding Number: PAR 27 096 Agency: National Institutes of Health Category: Health Funding Amount: $125,000 |
| BRAIN Initiative: Integrative Team-Research BRAIN Circuits Program - iBCP (RM1 Clinical Trial Not Allowed) Apply for RFA NS 27 002 Funding Number: RFA NS 27 002 Agency: National Institutes of Health Category: Health Funding Amount: $8,000,000 |
| Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional) Apply for PAR 28 062 Funding Number: PAR 28 062 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required) Apply for PAR 27 065 Funding Number: PAR 27 065 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required) Apply for RFA DK 27 139 Funding Number: RFA DK 27 139 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed) Apply for PAR 27 051 Funding Number: PAR 27 051 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional) Apply for PAR 27 127 Funding Number: PAR 27 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required) Apply for RFA CA 27 005 Funding Number: RFA CA 27 005 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| Limited Competition: Centers of Biomedical Research Excellence: Development Phase (COBRE-D) (P30 - Clinical Trial Not Allowed) Apply for PAR 27 054 Funding Number: PAR 27 054 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required) Apply for RFA DK 27 125 Funding Number: RFA DK 27 125 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cooperative Centers for Experimental Hematology (CCEHs) (U54- Clinical Trial Not Allowed) Apply for RFA DK 27 127 Funding Number: RFA DK 27 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA JG 26 0142", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.